Prostaglandins affect the central nervous system to produce hyperglycemia in rats.
The influence of prostaglandins (PG) on central nervous system regulation of blood sugar homeostasis was studied in rats. Substances were injected into the third cerebral ventricle of anesthetized rats while rectal temperature and hepatic venous plasma glucose concentration were recorded. Stereotaxic microinjection of PGD2, E1, E2, and F2 alpha produced hyperglycemia and hyperthermia. The relative order of potency in hyperglycemia, PGF2 alpha greater than D2 greater than E1 greater than E2, was not consistent with that of hyperthermia, PGE2 greater than F2 alpha greater than E1 greater than D2, which suggests that hyperglycemia was a primary, not secondary, response to hyperthermia. Injection of PGF2 alpha caused a dose dependent (5-200 micrograms) increase in the hepatic venous plasma glucose level. Neither the injection of PGF2 alpha (50 micrograms) into the cortex nor into the systemic vein caused hyperglycemia. The injection of PGF2 alpha into the ventricle resulted in the increase of not only glucose, but also glucagon, epinephrine, and norephinephrine in the hepatic venous plasma. However, constant infusion of somatostatin through the femoral vein completely prevented the increase of glucagon after administration of PGF2 alpha, although the increase of plasma glucose level was still observed. PGF2 alpha-induced hyperglycemia did not occur in adrenodemedullated rats. Intravenous injection of naloxone or propranolol did not affect the hyperglycemia, but phentolamine significantly prevented the hyperglycemic effect of PGF2 alpha. These results suggest that intraventricular PGF2 alpha affects the central nervous system to produce hyperglycemia by increasing epinephrine secretion from the adrenal medulla.
Yatomi
A
A
Iguchi
A
A
Yanagisawa
S
S
Matsunaga
H
H
Niki
I
I
Sakamoto
N
N
D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D001831:Body Temperature / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects* / Q000502:physiology; D015237:Dinoprost; D015232:Dinoprostone; D004837:Epinephrine / Q000097:blood; D005934:Glucagon / Q000097:blood; D006503:Hepatic Veins; D007276:Injections, Intraventricular; D008297:Male; D009638:Norepinephrine / Q000097:blood; D015230:Prostaglandin D2; D011453:Prostaglandins / Q000494:pharmacology*; D011457:Prostaglandins D / Q000494:pharmacology; D011458:Prostaglandins E / Q000494:pharmacology; D011460:Prostaglandins F / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains
D001786:Blood Glucose; D011453:Prostaglandins; D011457:Prostaglandins D; D011458:Prostaglandins E; D011460:Prostaglandins F; D005934:Glucagon; D015237:Dinoprost; D000527:Alprostadil; D015232:Dinoprostone; D015230:Prostaglandin D2; D009638:Norepinephrine; D004837:Epinephrine